• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用体外数据评估肝清除率预测:重点关注血浆中未结合分数和药物离解度,使用 107 种药物的数据库。

Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs.

机构信息

Centre for Applied Pharmacokinetic Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester M13 9PT, United Kingdom.

出版信息

J Pharm Sci. 2012 Aug;101(8):2645-52. doi: 10.1002/jps.23202. Epub 2012 Jun 14.

DOI:10.1002/jps.23202
PMID:22700322
Abstract

Underprediction of in vivo intrinsic clearance (CL(int)) of unbound drug from human hepatic in vitro systems using physiological extrapolation methodology is accepted as a common outcome. Poulin et al. (2012. J Pharm Sci 101:838-851) recently proposed an approach involving determination of effective fraction unbound in plasma (fu(p)) based on albumin-facilitated hepatic uptake of acidic/neutral drugs which improved prediction accuracy and precision for 25 drugs highly bound to plasma proteins. This approach includes correction of unbound drug according to the ionisation fraction either side of the plasma membrane based on pH difference. Here, we assessed the proposed method using a larger database of predictions of CL(int) for 107 drugs involving hepatocytes (89 drugs) and microsomes (64 drugs). The proposed method was similarly effective in minimising average prediction bias (to within twofold), unlike the conventional fu(p) correction method. However, precision was similar between methods and there was no evidence in the larger database that prediction bias was associated with fu(p). Prediction bias for hepatocytes was clearance dependent by either method, indicating important sources of bias from in vitro methodology. Therefore, to progress beyond empirical correction of bias, there is further need of mechanistic elucidation to improve prediction methodology.

摘要

在使用生理外推方法从人体肝体外系统预测未结合药物的体内内在清除率 (CL(int)) 时,预测值低于实际值是一种常见的结果。Poulin 等人(2012. J Pharm Sci 101:838-851)最近提出了一种方法,涉及根据白蛋白促进的酸性/中性药物在肝脏中的摄取来确定血浆中有效游离分数 (fu(p)),该方法提高了 25 种与血浆蛋白高度结合的药物的预测准确性和精密度。该方法包括根据细胞膜两侧的离子化分数对未结合药物进行校正,校正值基于 pH 差异。在这里,我们使用包含 107 种药物的更大的 CL(int)预测数据库(涉及肝细胞 89 种药物和微粒体 64 种药物)评估了该方法。与传统的 fu(p)校正方法不同,该方法同样能够有效地最小化平均预测偏差(在两倍以内)。然而,两种方法的精度相似,并且在更大的数据库中没有证据表明预测偏差与 fu(p)有关。两种方法预测的肝细胞清除率均依赖于清除率,这表明体外方法存在重要的偏差来源。因此,要想超越对偏差的经验性校正,需要进一步阐明机制以改进预测方法。

相似文献

1
Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs.使用体外数据评估肝清除率预测:重点关注血浆中未结合分数和药物离解度,使用 107 种药物的数据库。
J Pharm Sci. 2012 Aug;101(8):2645-52. doi: 10.1002/jps.23202. Epub 2012 Jun 14.
2
Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: emphasis on an apparent fraction unbound in liver for drugs.通过在体外-体内外推方法中结合代谢、转运和通透性数据来预测总肝清除率:重点关注药物在肝脏中的表观未结合分数。
J Pharm Sci. 2013 Jul;102(7):2085-95. doi: 10.1002/jps.23562. Epub 2013 Apr 23.
3
First-in-Human Predictions of Hepatic Clearance for Drugs With the Well-Stirred Model: Comparative Assessment Between Models of Fraction Unbound Based Either on the Free Drug Hypothesis, Albumin-Facilitated Hepatic Uptake or Dynamic Binding Kinetics.基于自由药物假说、白蛋白促进肝摄取或动态结合动力学的分数未结合模型预测具有搅拌池模型的药物在人体内的肝清除率:模型比较评估。
J Pharm Sci. 2024 Aug;113(8):2641-2650. doi: 10.1016/j.xphs.2024.05.021. Epub 2024 May 24.
4
Direct determination of the ratio of unbound fraction in plasma to unbound fraction in microsomal system (fu p/fu mic) for refined prediction of phase I mediated metabolic hepatic clearance.直接测定血浆中游离分数与微粒体系统中游离分数的比值(fu p/fu mic),以精确预测I相介导的肝脏代谢清除率。
J Pharmacol Toxicol Methods. 2011 Jan-Feb;63(1):35-9. doi: 10.1016/j.vascn.2010.04.003. Epub 2010 Apr 28.
5
A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes.一种基于肝细胞和微粒体体外内在清除率数据预测人体肝脏代谢清除率的统一模型。
Drug Metab Dispos. 2005 Sep;33(9):1304-11. doi: 10.1124/dmd.105.004259. Epub 2005 Jun 2.
6
Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data.从肝细胞数据推断人体代谢清除率的体外-体内外推新范例。
J Pharm Sci. 2013 Sep;102(9):3239-51. doi: 10.1002/jps.23502. Epub 2013 Mar 12.
7
Prediction of human pharmacokinetics--evaluation of methods for prediction of hepatic metabolic clearance.人体药代动力学预测——肝代谢清除率预测方法的评估
J Pharm Pharmacol. 2007 Jun;59(6):803-28. doi: 10.1211/jpp.59.6.0007.
8
Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data.药物在肝细胞中的结合:利用微粒体结合或药物亲脂性数据校正肝细胞孵育中未结合部分。
Drug Metab Dispos. 2008 Jul;36(7):1194-7. doi: 10.1124/dmd.108.020834. Epub 2008 Apr 14.
9
Prediction of human pharmacokinetics--improving microsome-based predictions of hepatic metabolic clearance.人体药代动力学预测——改进基于微粒体的肝脏代谢清除率预测
J Pharm Pharmacol. 2007 Oct;59(10):1427-31. doi: 10.1211/jpp.59.10.0014.
10
Improving Prediction of Metabolic Clearance Using Quantitative Extrapolation of Results Obtained From Human Hepatic Micropatterned Cocultures Model and by Considering the Impact of Albumin Binding.利用从人源肝微图案共培养模型中获得的定量外推结果并考虑白蛋白结合的影响来提高代谢清除率的预测。
J Pharm Sci. 2018 Jul;107(7):1957-1972. doi: 10.1016/j.xphs.2018.03.001. Epub 2018 Mar 7.

引用本文的文献

1
In Vitro-In Vivo Extrapolation of Hepatic Biotransformation Data for Fish. III. An In-depth Case Study with Pyrene.体外-体内外推鱼类肝生物转化数据。III. 以苊为例的深入案例研究。
Environ Toxicol Chem. 2023 Jul;42(7):1501-1515. doi: 10.1002/etc.5626. Epub 2023 May 17.
2
Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4.咪达唑仑作为由 CYP3A4 介导的异质药物-药物相互作用的探针。
Biomolecules. 2022 Jun 20;12(6):853. doi: 10.3390/biom12060853.
3
Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery.
高通量生理药代动力学(HT-PBPK)建模预测在早期药物发现中的成功评估。
Mol Pharm. 2022 Jul 4;19(7):2203-2216. doi: 10.1021/acs.molpharmaceut.2c00040. Epub 2022 Apr 27.
4
In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species.在体 - 体外预测临床前种属肝清除率。
Pharm Res. 2022 Jul;39(7):1615-1632. doi: 10.1007/s11095-022-03205-1. Epub 2022 Mar 7.
5
Recent developments in and models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.临床前药代动力学和药效学数据转化的 和 模型的最新进展。
Drug Metab Rev. 2021 May;53(2):207-233. doi: 10.1080/03602532.2021.1922435. Epub 2021 May 25.
6
Investigating the Theoretical Basis for In Vitro-In Vivo Extrapolation (IVIVE) in Predicting Drug Metabolic Clearance and Proposing Future Experimental Pathways.探讨体外-体内外推(IVIVE)预测药物代谢清除率的理论基础,并提出未来的实验途径。
AAPS J. 2020 Sep 10;22(5):120. doi: 10.1208/s12248-020-00501-9.
7
Relevance of In Vitro Metabolism Models to PET Radiotracer Development: Prediction of In Vivo Clearance in Rats from Microsomal Stability Data.体外代谢模型与正电子发射断层显像(PET)放射性示踪剂研发的相关性:根据微粒体稳定性数据预测大鼠体内清除率
Pharmaceuticals (Basel). 2019 Apr 14;12(2):57. doi: 10.3390/ph12020057.
8
Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling.用于预测人体药代动力学参数的非临床数据解读:体外-体内外推法和异速生长标度法
Pharmaceutics. 2019 Apr 5;11(4):168. doi: 10.3390/pharmaceutics11040168.
9
An examination of protein binding and protein-facilitated uptake relating to in vitro-in vivo extrapolation.探讨与体外-体内外推相关的蛋白结合和蛋白促进摄取。
Eur J Pharm Sci. 2018 Oct 15;123:502-514. doi: 10.1016/j.ejps.2018.08.008. Epub 2018 Aug 8.
10
Discovery of an Orally Bioavailable Inhibitor of Defective in Cullin Neddylation 1 (DCN1)-Mediated Cullin Neddylation.发现一种口服生物可利用的缺陷型 Cullin 连接酶 N 端赖氨酰化 1(DCN1)介导的 Cullin 连接酶 N 端赖氨酰化抑制剂。
J Med Chem. 2018 Apr 12;61(7):2694-2706. doi: 10.1021/acs.jmedchem.7b01282. Epub 2018 Mar 26.